Thomas Reiberger Selected Research

Neoplasms (Cancer)

1/2021	Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib.
12/2020	PIDDosome-induced p53-dependent ploidy restriction facilitates hepatocarcinogenesis.
2/2018	Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma.
1/2018	Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension.
1/2018	Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma.
12/2015	Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.
5/2015	CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
4/2014	Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Reiberger Research Topics

Disease

65	Fibrosis (Cirrhosis) 12/2022 - 01/2008
51	Portal Hypertension 10/2022 - 07/2011
50	Liver Diseases (Liver Disease) 10/2022 - 01/2015
27	Liver Cirrhosis (Hepatic Cirrhosis) 11/2022 - 06/2012
21	Hepatocellular Carcinoma (Hepatoma) 05/2022 - 04/2014
19	Hemorrhage 12/2022 - 11/2013
18	Infections 06/2022 - 07/2011
17	Inflammation (Inflammations) 06/2022 - 01/2008
16	Ascites 07/2022 - 01/2014
14	End Stage Liver Disease 10/2021 - 01/2017
10	Hepatitis C 10/2022 - 01/2013
9	Coinfection 06/2022 - 07/2010
8	Varicose Veins (Varicose Vein) 04/2022 - 11/2013
8	Neoplasms (Cancer) 01/2021 - 04/2014
7	Non-alcoholic Fatty Liver Disease 08/2022 - 03/2017
7	Disease Progression 06/2022 - 09/2019
6	Hepatic Encephalopathy 02/2021 - 01/2018
6	Chronic Hepatitis C 01/2021 - 01/2013
5	Acute-On-Chronic Liver Failure 01/2022 - 10/2017
4	COVID-19 12/2022 - 01/2021
4	Cholestasis 12/2022 - 02/2015
4	Anemia 12/2022 - 07/2011
4	Thrombosis (Thrombus) 01/2022 - 07/2018
4	Fatty Liver 01/2020 - 01/2018
4	Hypertension (High Blood Pressure) 09/2019 - 01/2017
3	Chronic Hepatitis B 06/2022 - 01/2012
3	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/2022 - 12/2020
3	Sepsis (Septicemia) 05/2021 - 11/2017
3	Acquired Immunodeficiency Syndrome (AIDS) 11/2013 - 08/2012
2	Thrombocytopenia (Thrombopenia) 12/2022 - 07/2011
2	Liver Failure 12/2022 - 01/2020
2	Alcoholic Liver Diseases (Alcoholic Liver Disease) 08/2022 - 01/2021
2	Hepatitis B 06/2022 - 01/2013
2	Liver Neoplasms (Liver Cancer) 04/2022 - 12/2015
2	Viremia 12/2021 - 01/2020
2	Hepatorenal Syndrome 05/2021 - 11/2018
2	Critical Illness (Critically Ill) 01/2021 - 11/2017
2	Cicatrix (Scar) 01/2020 - 01/2017

Drug/Important Bio-Agent (IBA)

18	4-(3-chlorophenylsulfanyl)piperidineIBA 02/2022 - 07/2011
14	InterferonsIBA 04/2022 - 01/2008
13	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2014
13	Antiviral Agents (Antivirals)IBA 01/2022 - 01/2008
11	RNA (Ribonucleic Acid)IBA 10/2022 - 01/2011
10	von Willebrand FactorIBA 08/2022 - 10/2012
10	AlbuminsIBA 04/2022 - 01/2018
9	C-Reactive ProteinIBA 01/2022 - 01/2018
8	Ribavirin (Virazole)FDA LinkGeneric 03/2018 - 07/2010
7	Proteins (Proteins, Gene)FDA Link 08/2022 - 01/2008
7	Alanine Transaminase (SGPT)IBA 01/2019 - 01/2008
6	Propranolol (Inderal)FDA LinkGeneric 07/2022 - 11/2013
5	gadolinium ethoxybenzyl DTPA FDA Link 10/2022 - 01/2017
5	Carvedilol (Coreg)FDA LinkGeneric 07/2022 - 11/2013
5	AntigensIBA 12/2021 - 10/2012
5	Sorafenib (BAY 43-9006)FDA Link 01/2021 - 11/2009
4	Carbon Tetrachloride (Tetrachloromethane)IBA 01/2022 - 08/2015
4	Transaminases (Aminotransferases)IBA 01/2022 - 02/2015
4	Interleukin-6 (Interleukin 6)IBA 12/2021 - 05/2013
4	CreatinineIBA 01/2021 - 11/2015
4	SodiumIBA 01/2021 - 09/2015
4	LipidsIBA 09/2019 - 03/2017
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2019 - 01/2015
3	BilirubinIBA 12/2022 - 12/2019
3	CollagenIBA 11/2022 - 04/2014
3	AnticoagulantsIBA 05/2022 - 07/2018
3	Bevacizumab (Avastin)FDA Link 01/2022 - 12/2015
3	ReninIBA 12/2021 - 01/2017
3	Bile Acids and Salts (Bile Acids)IBA 11/2021 - 01/2017
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2021 - 01/2018
3	Messenger RNA (mRNA)IBA 11/2020 - 11/2009
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2020 - 05/2016
3	Polytetrafluoroethylene (Teflon)FDA Link 01/2018 - 12/2017
3	InterleukinsIBA 03/2015 - 07/2011
2	TransferasesIBA 12/2022 - 01/2019
2	Complement C3 (C3 Complement)IBA 11/2022 - 01/2014
2	lipopolysaccharide-binding proteinIBA 01/2022 - 01/2017
2	bulevirtideIBA 01/2022 - 01/2022
2	ProcalcitoninIBA 01/2022 - 01/2021
2	Thrombin FDA Link 01/2022 - 01/2022
2	fibrin fragment D (D-dimer)IBA 01/2022 - 12/2021
2	atezolizumabIBA 01/2022 - 01/2022
2	AldosteroneIBA 12/2021 - 10/2021
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 11/2021 - 01/2012
2	Hormones (Hormone)IBA 10/2021 - 02/2019
2	Hydroxyproline (4 Hydroxyproline)IBA 01/2021 - 12/2020
2	Immune Checkpoint InhibitorsIBA 01/2021 - 05/2015
2	TerlipressinIBA 01/2021 - 11/2018
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2021 - 11/2019
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 01/2021
2	riociguatIBA 12/2020 - 01/2018
2	Vitamin A (Retinol)FDA LinkGeneric 12/2020 - 01/2020
2	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 12/2020 - 01/2020

Therapy/Procedure

37	Therapeutics 05/2022 - 01/2008
19	Liver Transplantation 06/2022 - 03/2017
12	Transjugular Intrahepatic Portasystemic Shunt 12/2022 - 09/2017
10	Surgical Portasystemic Shunt (Portosystemic Shunt) 12/2022 - 12/2017
9	Ligation 01/2022 - 11/2013
4	Stents 08/2022 - 12/2017
4	Immunotherapy 01/2022 - 05/2015
3	Transplantation 06/2022 - 10/2012
2	Contraindications 12/2022 - 05/2014